The Philippine President will be meeting Barack Obama in Laos next week on the sidelines of an East Asia summit.
Opioids now kill more people than auto accidents or guns. What can be done to curb this epidemic, with U.S. Surgeon General Vivek Murthy.
The only way to stop drug companies from jacking up the costs of live-saving treatments is through price controls, a former Obama health advisor says.
Chief pharmacy officer at the Cleveland Clinic discusses Mylan's "generic" version of its own product, the Epipen, on CNBC's "Closing Bell."
CNBC's Meg Tirrell reports on Mylan's decision to launch a generic EpiPen as a way of cutting the cost of the treatment.
Amid Mylan launching an EpiPen generic alternative, the “Fast Money Halftime Report” traders and CNBC’s Jim Cramer share their take on Mylan and the biotech sector.
There's a case for applying laws against profiteering to the drug industry, Dr. Joshua Sharfstein tells CNBC.
Bill Ackman tells CNBC the past 12 months were the "worst period of performance" of his career, and the implosion of Valeant Pharmaceuticals was mostly to blame.
CNBC’s Meg Tirrell reports the latest on Mylan prices and the drug price blame game.
Chris Kofinis, a Democratic strategist - who worked for Mylan CEO Heather Bresch's father, Sen. Joe Manchin - criticizes her response to the EpiPen "crisis."
Rep. Lloyd Doggett (D-Texas) discusses the EpiPen pricing saga and his views on greater price gouging in the drug industry with the "Fast Money" traders.
CNBC's Meg Tirrell reports the latest on the drug price debate, Teva on a generic EpiPen and the FDA. David Maris, Wells Fargo analyst, and the "FMHR" traders weigh in.
The "FMHR" panel and David Maris, specialty pharmaceutical analyst at Wells Fargo Securities, discuss the latest on the EpiPen pricing outrage.
Mylan's decision to "gouge" consumers on lifesaving EpiPen devices is corporate "greed on steroids," consumer advocate Ralph Nader tells CNBC.
Mylan CEO Heather Bresch speaks to CNBC on Thursday about the controversy surrounding her company's 400-percent price hike to EpiPens over the past few years.
Colombia's government and leftist FARC rebels unveiled a peace deal to end a guerrilla war which almost made the country a failed state.
Some people are decrying Duterte's drugs crackdown and the casualties while others are in support of it, says Teneo Holdings' Roberto Herrera-Lim.
De La Salle University's Richard Heydarian says the Philippines' president is under pressure to deliver on promises to be tough on crime and shake-up bureaucracy.
Clovis Oncology shares shot up more than 26 percent Tuesday after the FDA accepted the company's new drug application.
CNBC's Meg Tirrell reports the details on Pfizer's deal for Medivation.